DescriptionCurator's Comment:: description was created based on several sources, including:
http://www.touroinstitute.com/natural%20bactericidal.pdf
http://www.naturalcurelabs.com/monolaurin-top-10/
Curator's Comment:: description was created based on several sources, including:
http://www.touroinstitute.com/natural%20bactericidal.pdf
http://www.naturalcurelabs.com/monolaurin-top-10/
Monolaurin, derived naturally from coconut, is a source of the medium chain fatty acid lauric acid. Monolaurin has been widely researched for its antiviral, antibacterial, and antimicrobial properties, as it can break down and destroy the lipid layer of enveloped viruses where many pharmaceuticals fail. Fatty acids and monoglycerides produce their killing/inactivating effects by several mechanisms. An early postulated mechanism was the perturbing of the plasma membrane lipid bilayer. The antiviral action attributed to monolaurin is that of fluidizing the structure in the envelope of the virus, causing the disintegration of the microbial membrane. More recent studies, indicate that one antimicrobial effect in bacteria is related to monolaurin's interference with signal transduction/toxin formation. Another antimicrobial effect in viruses is due to lauric acid's interference with virus assembly and viral maturation. The third mode of action may be on the immune system itself. Monolaurin does not appear to have an adverse effect on desirable gut bacteria, but rather on only potentially pathogenic microorganisms. It is classified by the FDA as "generally regarded as safe" (GRAS).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P06886 Gene ID: NA Gene Symbol: tst Target Organism: Staphylococcus aureus |
|||
Target ID: CHEMBL4114 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8021206 |
|||
Target ID: CHEMBL1909490 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27366648 |
|||
Target ID: P01583 Gene ID: 3552.0 Gene Symbol: IL1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27366648 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Lauricidin Approved UseUnknown |
|||
Curative | Lauricidin Approved UseUnknown |
|||
Preventing | Lauricidin Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.lauricidin.com/instructions
The recommended initial level is ~0.75 gram or less two or three times daily for a week before increasing the amount. The level can be then increased to 1.5 grams one, two or three times daily thereafter. A maintenance level can be 3.0 grams two or three times a day necessary for optimum health effects. Take with or after meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4670656
MIC dose range of 1-Monolaurin for 10 susceptible organisms from groups A and D is 0,045 uM/ml - NI (not inhibitory at concentrations tested). Max concentration tested was 3,63 uM/ml.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
71892
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
||
|
DSLD |
4137 (Number of products:3)
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
||
|
NCI_THESAURUS |
C83486
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
||
|
EPA PESTICIDE CODE |
11290
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
||
|
DSLD |
3576 (Number of products:17)
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB22053
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
PRIMARY | |||
|
MONOLAURIN
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
PRIMARY | |||
|
27215-38-9
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
PRIMARY | |||
|
248-337-4
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
PRIMARY | |||
|
Y98611C087
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
PRIMARY | |||
|
27215-38-9
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
PRIMARY | |||
|
1311693
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
PRIMARY | |||
|
314647
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
ALTERNATIVE | |||
|
C75644
Created by
admin on Sat Jun 26 18:33:25 UTC 2021 , Edited by admin on Sat Jun 26 18:33:25 UTC 2021
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY